Genes Correlated with Gemcitabine Efficacy in Non-small Cell Lung Cancer

Chunhong Li1, Meiyan Liu1, Hailing Lu1, Wei Liu1, Li Cai* and Xiaoqun Dong**

1Department of Internal Medical Oncology, The Harbin Medical University Cancer Hospital, Harbin, P.R. China
2Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, The University of Rhode Island, Kingston, USA

Abstract

Objective: Gemcitabine in combination with platinum improves survival of patients with non-small cell lung cancer (NSCLC). The purpose of the study was to explore genes related to gemcitabine efficacy.

Methods: The sensitivity of NSCLC cell lines to anticancer drugs was tested via MTT assay. Gene expression analysis was performed by cDNA microarray, and qRT-PCR was used for verification of the microarray results on highly sensitive genes. Fluorouracil (5-Fu) was used as the negative control of gemcitabine.

Results: Gemcitabine-related and fluorouracil-related genes were pooled into different clusters. Genes negatively related to 5-Fu sensitivity were positively related to gemcitabine efficacy. Metallothionein, Cathepsin B, TIMP1 and Galectin-1 genes which were resisted to certain anticancer drugs were sensitive to gemcitabine (P<0.05).

Conclusion: Metallothionein, Cathepsin B, TIMP1 and Galectin-1 can be considered as the predictors for gemcitabine sensitivity.

Keywords: Gemcitabine; Chemotherapy sensitivity; Efficacy-related genes; Non-small cell lung cancer

Introduction

Non-small cell lung cancer (NSCLC) is the leading cause of cancer related death worldwide [1]. NSCLC is any type of epithelial lung cancer other than small cell lung cancer (SCLC). The most common types of NSCLC are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. NSCLC is relatively insensitive to chemotherapy compared to SCLC. Platinum-based combination chemotherapy is the standard treatment for NSCLC [2], including cisplatin plus gemcitabine [3], vinorelbine [4], paclitaxel [5], docetaxel [6] or pemetrexed [7]. Standard treatment for NSCLC [2], including cisplatin plus gemcitabine compared to SCLC. Platinum-based combination chemotherapy is the standard treatment for NSCLC [2], including cisplatin plus gemcitabine [3], vinorelbine [4], paclitaxel [5], docetaxel [6] or pemetrexed [7].

Materials and Methods

Cell culture and drugs

Six NSCLC cell lines (LK-2 [squamous cell carcinoma], PC-7 [adenocarcinoma], PC-9 [adenocarcinoma], PC-14 [adenocarcinoma], A549 [adenocarcinoma] and Lu65 [large cell carcinoma]) and BET2A were cultured in RPMI 1640 supplement with 5% fetal bovine serum at 37°C in humidified air containing 5% CO2. Gemcitabine was purchased from Lilly (America) and its concentration was adjusted to 0.05 μg/mL to 500 μg/mL. 5-Fu was purchased from Faulding (Australia) and its concentration was adjusted to 0.005 μg/mL to 10 μg/mL with dimethylsulphoxide (DMSO).

Measurement of cell sensitivity

Drug sensitivity was assessed by MTT assay [12]. Cells were seeded in 96 well tissue culture plates at an initial concentration of 1 × 10³ cells/mL and pre-treated with different concentrations of gemcitabine (500, 100, 50, 10, 5, 1, 0.2, 0.1, 0.04 μg/mL) or 5-FU (10, 5, 1, 0.2, 0.1, 0.01, 0.04, 0.001, 0.008 μg/mL) for 68 h. Then cells were treated by addition of 20 ml MTT dye to each well. After incubation for 4 h, the growth medium was removed and the formazan crystals, formed by oxidation of the MTT dye, were dissolved with 200 μl DMSO in isopropanol. The absorbance was measured at 560 nm and the cell survival ratio was expressed as a percentage of the control. The IC₅₀ was calculated using Reed-Muench method [13].

mRNA extraction and labelling

Total RNA was extracted with Trizol reagent (Invitrogen, Carlsbad, CA). The mRNA was obtained with oligo-dT-magnetic beads (Toyobo Co, Osaka, Japan). For cDNA synthesis, River Trace (Toyobo Co, Osaka, Japan) was used. Probes were synthesized and labelled from 4 μg of amplified RNA. In brief, 4 μg of amplified RNA were combined with 4 μg amine-modified random primer and 5 units of RNAase inhibitor (SUPERase, Ambion). The mixture was incubated at 70°C for 10 min, then chilled on ice for 10 min, and left at room temperature for 10 min. Primer RNA solution was added to the reverse transcriptase mix (including 0.5 mM dATP, dGTP, dCTP, 0.3 mM dTTP, and 0.2

*Corresponding author: Li Cai, Department of Internal Medical Oncology, The Harbin Medical University Cancer Hospital, Harbin, 150040, P.R. China, Tel: +86-451-86296283; Fax: +86-451-86296735; E-mail: cai366@126.com
Xiaoqun Dong, M.D., Ph.D., Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, The University of Rhode Island, Pharmacy Building, 7 Greenhouse Road, Kingston, RI 02881, USA, Tel: +1 401-874-4805; Fax: +1 401-874-5787; E-mail: xiaoqun_dong@uri.edu

Received June 11, 2018; Accepted July 17, 2018; Published July 19, 2018

Citation: Li C, Liu M, Lu H, Liu W, Cai L, et al. (2018) Genes Correlated with Gemcitabine Efficacy in Non-small Cell Lung Cancer. J Cancer Sci Ther 10: 169-172. doi: 10.4172/1948-5956.1000540

Copyright: © 2018 Li C, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Gene expression profiling data related to the activity of gemcitabine and 5-Fu was shown in Figure 1. The profile of gene expression was clustered well, and high consistency of gene expression existed in gemcitabine-group as well as in 5-Fu-group. Moreover, activity-related genes in gemcitabine-group were gathered into a cluster, while genes in the 5-Fu-group came together into another cluster. The activity-related genes with gemcitabine were mainly divided into the following 5 categories: Signal transduction molecules, growth factor, growth factor receptors, apoptosis cascade and transcription factors (Table 2).

36 genes were related with gemcitabine activity. Most genes positively related with gemcitabine activity were negatively related to 5-Fu activity. Among genes differentially expressed, Metallothionein, Cathepsin B, TIMP1 and Galectin-1 were highly positively associated with the sensitivity of gemcitabine (P<0.05) (Table 3). Drug activity-related genes Metallothionein and TIMP-1 were selected to test microarray data by semi-quantitative RT-PCR (Figure 2). The result of RT-PCR was in consistent with cDNA microarray data.

**Discussion**
Chemotherapy is a crucial treatment against lung cancer. The same chemotherapeutic medicine is frequently used for patients with different types of cancer. Meanwhile, the different anticancer drugs are applied in patients with the same type of cancer. It is due to certain genes existed in tumours that respond to certain drugs. Therefore, it is important to find out drug sensitivity-related genes in choosing an effective chemotherapy regimen. Much effort has been put on the relation between resistant genes and anticancer drugs. Patients with an increased expression of excision repair cross complementation group-1 (ERCC1) or ribonucleotide reductase subunit M1 (RRM1) may benefit less from cisplatin-based and gemcitabine-based chemotherapy, respectively [14]. Overexpression of P-glycoprotein is associated with taxanes resistance. Clinical studies support a relationship between

| Cell Lines | IC50 (μg/ml) | GEM | 5-Fu |
|------------|-------------|-----|------|
| Lu65       | 79.533 ± 10.854 | 8.759 ± 1.007 |
| PK-2       | 54.607 ± 7.989 | >10 |
| PC-9       | 14.210 ± 3.571 | 5.843 ± 2.239 |
| PC-7       | <0.050 | 2.760 ± 1.174 |
| PC14       | >500 | >10 |
| AS49       | >500 | >10 |

*GEM: Gemcitabine; 5-Fu: 5-Fluorouracil

**Table 1: Growth inhibitory activities (IC50) of anticancer agents against the lung cancer cell lines.**

Gene expression profiling data related to the activity of gemcitabine and 5-Fu was shown in Figure 1. The profile of gene expression was clustered well, and high consistency of gene expression existed in gemcitabine-group as well as in 5-Fu-group. Moreover, activity-related genes in gemcitabine-group were gathered into a cluster, while genes in the 5-Fu-group came together into another cluster. The activity-related genes with gemcitabine were mainly divided into the following 5 categories: Signal transduction molecules, growth factor, growth factor receptors, apoptosis cascade and transcription factors (Table 2).

36 genes were related with gemcitabine activity. Most genes positively related with gemcitabine activity were negatively related to 5-Fu activity. Among genes differentially expressed, Metallothionein, Cathepsin B, TIMP1 and Galectin-1 were highly positively associated with the sensitivity of gemcitabine (P<0.05) (Table 3). Drug activity-related genes Metallothionein and TIMP-1 were selected to test microarray data by semi-quantitative RT-PCR (Figure 2). The result of RT-PCR was in consistent with cDNA microarray data.

**Discussion**
Chemotherapy is a crucial treatment against lung cancer. The same chemotherapeutic medicine is frequently used for patients with different types of cancer. Meanwhile, the different anticancer drugs are applied in patients with the same type of cancer. It is due to certain genes existed in tumours that respond to certain drugs. Therefore, it is important to find out drug sensitivity-related genes in choosing an effective chemotherapy regimen. Much effort has been put on the relation between resistant genes and anticancer drugs. Patients with an increased expression of excision repair cross complementation group-1 (ERCC1) or ribonucleotide reductase subunit M1 (RRM1) may benefit less from cisplatin-based and gemcitabine-based chemotherapy, respectively [14]. Overexpression of P-glycoprotein is associated with taxanes resistance. Clinical studies support a relationship between

| Cell Lines | IC50 (μg/ml) | GEM | 5-Fu |
|------------|-------------|-----|------|
| Lu65       | 79.533 ± 10.854 | 8.759 ± 1.007 |
| PK-2       | 54.607 ± 7.989 | >10 |
| PC-9       | 14.210 ± 3.571 | 5.843 ± 2.239 |
| PC-7       | <0.050 | 2.760 ± 1.174 |
| PC14       | >500 | >10 |
| AS49       | >500 | >10 |

*GEM: Gemcitabine; 5-Fu: 5-Fluorouracil

**Table 1: Growth inhibitory activities (IC50) of anticancer agents against the lung cancer cell lines.**

Gene expression profiling data related to the activity of gemcitabine and 5-Fu was shown in Figure 1. The profile of gene expression was clustered well, and high consistency of gene expression existed in gemcitabine-group as well as in 5-Fu-group. Moreover, activity-related genes in gemcitabine-group were gathered into a cluster, while genes in the 5-Fu-group came together into another cluster. The activity-related genes with gemcitabine were mainly divided into the following 5 categories: Signal transduction molecules, growth factor, growth factor receptors, apoptosis cascade and transcription factors (Table 2).

36 genes were related with gemcitabine activity. Most genes positively related with gemcitabine activity were negatively related to 5-Fu activity. Among genes differentially expressed, Metallothionein, Cathepsin B, TIMP1 and Galectin-1 were highly positively associated with the sensitivity of gemcitabine (P<0.05) (Table 3). Drug activity-related genes Metallothionein and TIMP-1 were selected to test microarray data by semi-quantitative RT-PCR (Figure 2). The result of RT-PCR was in consistent with cDNA microarray data.

**Discussion**
Chemotherapy is a crucial treatment against lung cancer. The same chemotherapeutic medicine is frequently used for patients with different types of cancer. Meanwhile, the different anticancer drugs are applied in patients with the same type of cancer. It is due to certain genes existed in tumours that respond to certain drugs. Therefore, it is important to find out drug sensitivity-related genes in choosing an effective chemotherapy regimen. Much effort has been put on the relation between resistant genes and anticancer drugs. Patients with an increased expression of excision repair cross complementation group-1 (ERCC1) or ribonucleotide reductase subunit M1 (RRM1) may benefit less from cisplatin-based and gemcitabine-based chemotherapy, respectively [14]. Overexpression of P-glycoprotein is associated with taxanes resistance. Clinical studies support a relationship between
Gemcitabine and 5-Fu are anticancer drugs acting on cancer metabolism [17,18]. Gemcitabine (dFdC) [19] is phosphorylated into the better prediction for treatment response. If several markers are detected in combination, it will provide focused on the association between single gene and single drug in with less response of oxaliplatin treatment [16]. However, most studies Phosphohydroxythreonine aminotransferase (PSAT1) was related poor response to taxanes and overexpression of beta III-tubulin [15]. Therefore, 5-Fu was used for a negative control to gemcitabine in cancer. If several markers are detected in combination, it will provide the better prediction for treatment response.

Gemcitabine and 5-Fu are anticancer drugs acting on cancer metabolism [17,18]. Gemcitabine (dFdC) [19] is phosphorylated into gemcitabine monophosphate (dFdCMP) by deoxycytidine kinase (dCK), and subsequently phosphorylated to gemcitabine diphosphate (dFdCDP) by pyrimidine nucleoside monophosphate kinase and gemcitabine triphosphate (dFdCTP) by nucleoside diphosphate kinase (NDPK). dFdCTP is incorporated into DNA during replication, and inhibited chain elongation of DNA and cause cell apoptosis. Gemcitabine is rapidly metabolized by cytidine deaminase in liver, kidney, blood and other tissues. A half-life (t1/2) of Gemcitabine is 30 to 90 minutes associated with age and sex. Fluorouracil [20] is transformed into a 5-fluoro-2-deoxyuracil nucleotide, which inhibit thymine nucleotide synthetase, block Deoxyuracil nucleotide into Deoxothymine nucleotide and inhibit the biosynthesis of DNA. Fluorouracil is mainly metabolized by the liver, and is decomposed into carbon dioxide, about 15% of prototype medicine out of the body by the kidney. Large doses of the drug can pass through the blood-brain barrier and reach the cerebrospinal fluid after intravenous infusion for half an hour, lasting 3 hours. t1/2α is 10-20 minutes, and t1/2β is 20 hours. Although it is similar to gemcitabine in antitumor mechanism, 5-Fu is rarely applied in NSCLC treatment, while gemcitabine frequently appears in chemotherapy regimens against NSCLC [21].

**Conclusion**

Therefore, 5-Fu was used for a negative control to gemcitabine in the study. The study data showed that genes positively connected with gemcitabine were mainly negatively connected with 5-Fu, which can be a reason for the lack of 5-Fu in NSCLC treatment. Metallothionein, Cathepsin B, TIMP1 and Galectin-1 were highly positively associated

### Table 2: Classification of sensitive gene to gemcitabine (GEM) and 5-fluorouracil (5-Fu) in 6 lung cancer cell lines.

| Classification | GEM (Gene Number) | 5-Fu (Gene Number) |
|----------------|-------------------|--------------------|
| Signal transduction molecule | 11 | 11 |
| Growth factor receptor | 4 | 4 |
| Growth factor | 6 | 6 |
| Apoptosis related | 2 | 2 |
| Cell factor | 1 | 1 |
| Cyclin protein | 1 | 1 |
| Transcription factor | 1 | 1 |
| Metabolism-related enzymes and inhibitors | 1 | 1 |
| Proteolysis | 1 | 1 |
| Molecular chaperone | 1 | 1 |
| Cell surface receptor | 0 | 0 |
| Development process factor | 0 | 0 |
| Others | 7 | 10 |
| Total | 36 | 39 |

*Refers to non-classified genes

### Table 3: Genes related with drug activity of gemcitabine and 5-fluorouracil in NSCLC.

| Entering serial number | Genes | GEM | 5-Fu |
|------------------------|-------|-----|------|
| X64177 | Metallothionein | 0.731 | -0.734 |
| L16510 | Cathepsin B | 0.715 | -0.723 |
| X03124 | TIMP1 | 0.700 | -0.692 |
| J04456 | Galectin-1 | 0.695 | -0.702 |
| X55313 | TNF-R1 | 0.621 | -0.636 |
| * TGF, beta-induced, 68KD | 0.572 | -0.596 |
| X12451 | Cathepsin L | 0.550 | -0.566 |
| M16006 | PAI-1 | 0.503 | -0.525 |
| * | Annexin 11 | 0.506 | -0.530 |
| M62403 | IGFBP4 | 0.574 | -0.588 |
| X51675 | UPAR | 0.493 | -0.508 |
| U61276 | Jagged | 0.426 | -0.450 |
| U03864 | Alpha A-AR | 0.585 | -0.582 |
| M59371 | Epha2 | 0.525 | -0.543 |
| X13276 | CD13 | 0.456 | -0.470 |
| U66075 | GATA-6 | 0.441 | -0.466 |
| M74088 | APC | 0.421 | -0.433 |
| * Fibromodulin | 0.431 | -0.454 |
| AB002409 | SLC | 0.400 | -0.420 |
| M14113 | Procoagulant | -0.45 | 0.421 |
| M66722 | Clusterin | 0.610 | -0.632 |
| U20240 | C/EBP gamma | 0.412 | -0.435 |
| J04456 | HSP32 | 0.451 | -0.471 |
| Y00371 | HSC 70 | 0.532 | -0.548 |
| L25081 | Rho C | 0.473 | -0.487 |
| M87770 | FGFR-2 | 0.542 | -0.550 |
| X14787 | Thrombospondin 1 | 0.516 | -0.517 |
| M33680 | CD81 | 0.406 | -0.435 |
| * Thymosin beta 10 | 0.412 | -0.436 |
| U22322 | Rak | 0.415 | -0.426 |
| * | Lactate dehydrogenase A | 0.416 | -0.431 |
| U01877 | P300 | 0.419 | -0.436 |
| X61615 | LIFR | 0.403 | -0.422 |
| Z12020 | MDM2 | -0.435 | 0.417 |
| AF101264 | CaMKK | -0.407 | -- |
| J03817 | GSTM1B | -- | -0.401 |
| M15518 | TPA | -0.413 | -- |
| J04765 | CD29 | -- | -0.408 |
| X15804 | Osteopontin | -- | -0.410 |
| L20688 | Alpha-actin | -- | -0.409 |
| * | Rho GDI beta | -- | 0.415 |

*Refers to non-classified genes. GEM: gemcitabine. 5-Fu: 5-fluorouracil. The number means Pearson correlation coefficient. Pearson correlation coefficient ≥ 0.632, P<0.05; Pearson correlation coefficient ≥ 0.715, P<0.02
with the sensitivity of gemcitabine. The four genes can be considered as gemcitabine efficacy-related genes which may be applied clinically to predict the response of gemcitabine in NSCLC. To gemcitabine-insensitivity patients, gemcitabine should be exclude in treatment regimen, and avoid the adverse effects including difficulty breathing, low white and red blood cells counts and low platelet counts, vomiting and nausea, elevated transaminases, rashes and itchy skin, hair loss, blood and protein in urine, flu-like symptoms, edema, fever, loss of appetite, headache, difficulty sleeping, tiredness, cough, runny nose, diarrhea, mouth and lip sores, sweating, back pain, and muscle pain.

Metallothionein (MT) expression level is related with drug resistance in a variety of malignancies including NSCLC. MTs play important roles in the resistance of tumour cells to cisplatin [22]. Cathepsins B (CTSB) is involved in tumorigenesis, angiogenesis, invasion and metastasis [23]. Over-expression of CTSB is correlated with poor prognosis and increases incidence of distant metastases. CTSB is connected with drug resistance [24]. TIMP-1 influences cell growth and apoptosis [25]. TIMP-1 levels were significantly associated with a poor response to chemotherapy in patients with metastatic breast cancer, and TIMP-1 is resistant to the most frequently used chemotherapy regimens of cyclophosphamide/methotrexate/5-Fu [26]. Galectin-1 knockdown sensitized lung cancer cells to platinum-based chemotherapy (cisplatin) [27]. The above-mentioned genes which are reported resistant to certain anticancer drugs are unexpectedly sensitive to gemcitabine in our study. The observation provided theoretical evidence in explaining why gemcitabine produces a good survival benefit against other agents in the combination with platinum. In fact, it has been reported that gemcitabine can increase the sensitivity of both cisplatin-sensitive and cisplatin-resistant cell lines [28].

Future medication will be tailored based on the individual's genetics. A number of potential biomarkers are under investigation with an attempt to provide optimal therapies. The results can provide potential biomarkers for the prediction of gemcitabine efficacy and afford potential targets to overcome gemcitabine resistance in NSCLC patients.

Acknowledgement

The fund of this study was supported by education department of Heilongjiang province (12541512).

References

1. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, et al. (2005) Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97: 1407-1427.
2. Piklington G, Boland A, Brown T, Oyej, Bagust A, et al. (2015) A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer. Thorax 70: 359-367.
3. Reck M, Von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, et al. (2010) Le Chevalier T, Scagliotti G, Natale R, Danson S, Rosell R, et al. (2005) Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 17: 3522-3530.
4. Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, et al. (2002) First-line chemotherapy (cisplatin) [27]. The above-mentioned genes which are reported resistant to certain anticancer drugs are unexpectedly sensitive to gemcitabine in our study. The observation provided theoretical evidence in explaining why gemcitabine produces a good survival benefit against other agents in the combination with platinum. In fact, it has been reported that gemcitabine can increase the sensitivity of both cisplatin-sensitive and cisplatin-resistant cell lines [28].

Future medication will be tailored based on the individual's genetics. A number of potential biomarkers are under investigation with an attempt to provide optimal therapies. The results can provide potential biomarkers for the prediction of gemcitabine efficacy and afford potential targets to overcome gemcitabine resistance in NSCLC patients.

Acknowledgement

The fund of this study was supported by education department of Heilongjiang province (12541512).

References

1. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, et al. (2005) Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97: 1407-1427.
2. Piklington G, Boland A, Brown T, Oyej, Bagust A, et al. (2015) A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer. Thorax 70: 359-367.
3. Reck M, Von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, et al. (2010) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab in patients with advanced non-small cell lung cancer. J Clin Oncol 18: 2017-2027.
4. Araya T, Kasahara K, Kimura H, Shibata K, Kita T, et al. (2007) Bi-weekly administration of gemcitabine plus vinorelbine in elderly patients with advanced non-small-cell lung cancer: Multicenter phase II trial. Lung Cancer 56: 371-376.
5. Bengsch F, Buck A, Günther SC, Seiz JR, Tacke M, et al. (1997) Cell type-dependent pathogenic functions of overexpressed human cathepsin B in murine breast cancer progression. Oncogene 33: 4474-4484.
6. Lim IT, Mercoue SO, Lee M, Heeg MJ, Mobashery S (2014) Strategy in Cell type-dependent pathogenic functions of overexpressed human cathepsin B in murine breast cancer progression. Oncoogene 33: 4474-4484.
7. Peters GJ, Van Moorsel CJ, Lakerveld B, Smid K, Noordhuis P, et al. (2013) Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK, and cyclooxygenase-2. Clin Cancer Res 18: 4037-4047.
8. Peters GJ, Van Moorsel CJ, Lakerveld B, Smid K, Noordhuis P, et al. (2006) Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines. 28: 237-244.